Real-World data: does adding immunotherapy before lung surgery improve outcomes?

NCT ID NCT07169708

Recruiting now Knowledge-focused Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviews medical records of 100 adults in Taiwan with resectable non-small cell lung cancer who received nivolumab (an immunotherapy) combined with chemotherapy before surgery. Researchers want to see if this approach helps shrink tumors completely and delays cancer return, and whether it is safe. The study does not give any new treatment—it only looks at data from routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Chang Gung Memorial Hospital Kaohsiung Branch
RECRUITING

Kaohsiung City, Taiwan
Chang Gung Memorial Hospital Linkou Branch
RECRUITING

Taoyuan, Taiwan
China Medical University Hospital
RECRUITING

Taichung, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
RECRUITING

Kaohsiung City, Taiwan
Kaohsiung Veterns General Hospital
RECRUITING

Kaohsiung City, Taiwan
Mackay Memorial Hospital Taipei Branch
RECRUITING

Taipei, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, Taiwan
Taichung Veterans General Hospital
RECRUITING

Taichung, Taiwan
Taipei Veteran General Hospital
RECRUITING

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.